- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04188535
Serial MRI Scans During Radiation Therapy (RELAY)
RELAY: Repeated Magnetic Resonance Imaging Examinations to Analyze and Assess Your Cancer: A Prospective Study on the Use of Serial Magnetic Resonance Imaging in the Assessment of Changes During Treatment With Radiation Therapy
This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma.
The research study procedures include three MRI scans (one before, one during, and one after standard of care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma.
The research study procedures include:
- Screening for eligibility
- Three MRI scans
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1, non-randomized, open-label study evaluating feasibility of serial MRI, with an option for an expansion cohort. The optional expansion cohort is a prospective imaging registry evaluating imaging biomarkers as predictors of disease control with standard of care treatment.
This research study is a feasibility study, meaning that it is the first time that investigators at this institution are examining the process of getting multiple MRIs during radiation treatment.
The U.S. Food and Drug Administration (FDA) has cleared this MRI scanner for use.
Participants who fulfill eligibility criteria will be entered into the trial.
The research study procedures include screening for eligibility, and three MRI scans. MRI imaging will be performed as per disease site standards.
A total of 139 participants will be enrolled in this trial:
- 13 participants in the esophageal cancer cohort
- 10 participants in the initial glioblastoma cohort and 36 participants in the image registry expansion cohort
- 10 participants in the prostate cancer cohort and 50 participants in the image registry expansion cohort
- 10 participants in the vulvar cancer cohort
- 10 participants in the pediatric glioma cohort
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jonathan Leeman, MD
- Phone Number: (617) 732-6452
- Email: JONATHANE_LEEMAN@DFCI.HARVARD.EDU
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana Farber Cancer Institute
-
Principal Investigator:
- Jonathan Leeman, MD
-
Contact:
- Jonathan Leeman, MD
- Phone Number: 617-732-6452
- Email: JONATHANE_LEEMAN@DFCI.HARVARD.EDU
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women Hospital
-
Contact:
- Jonathan Leeman, MD
- Email: JONATHANE_LEEMAN@DFCI.HARVARD.EDU
-
Principal Investigator:
- Jonathan Leeman, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must have a confirmed malignancy requiring radiation therapy.
- Age: 18 years or older except where otherwise specified in subprotocol.
- ECOG performance status ≤2 (Karnofsky ≥60%)
- Ability to understand and the willingness to sign a written informed consent document.
- Any further criteria listed in the specific disease site subprotocol.
- (Esophageal cohort) Patients must be considered appropriate candidates for neoadjuvant chemoradiation therapy followed by esophagectomy. Patients must have an endoscopic ultrasound done or scheduled to be done at the baseline visit.
- (Glioblastoma cohort) Patients with a histologically confirmed newly diagnosed intracranial glioblastoma or gliosarcoma who will be undergoing radiation therapy as part of clinical care.
- (Prostate cohort) Patients with localized prostate cancer who are planning to receive androgen deprivation therapy and definitive radiation therapy.
- (Vulvar cohort) Patients with biopsy-proven locally advanced vulvar cancer for which definitive radiotherapy is planned.
- (Pediatric glioma cohort) Patients age 18 or under (patients 18-30 years old are also eligible if the physician determines that based on genetics, the tumor biology is consistent with pediatric high grade glioma). Patients with a histologically confirmed newly diagnosed high-grade glioma (WHO grade III or IV) who will be undergoing radiation therapy as part of clinical care. Patients with DIPG are only eligible if biopsy-confirmed high grade DIPG is present. Ability to understand and/or willingness of their parent or legally authorized representative to sign a written informed consent document.
Exclusion Criteria:
- Disease-specific exclusion criteria will be specified in a subprotocol.
- For MRI involving contrast, history of allergic reactions attributed to gadolinium-based IV contrast. If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility.
- Inability to undergo magnetic resonance imaging (MRI).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Esophageal Cohort
The research study procedures include:
|
Imaging with MRI will be performed as per disease site standards.
|
Experimental: Glioblastoma Cohort
The research study procedures include:
|
Imaging with MRI will be performed as per disease site standards.
|
Experimental: Glioblastoma Expansion Cohort Serial MR Imaging Registry
The research study procedures include:
|
Imaging with MRI will be performed as per disease site standards.
|
Experimental: Prostate Cancer Cohort
The research study procedures include:
|
Imaging with MRI will be performed as per disease site standards.
|
Experimental: Prostate Cancer Expansion Cohort Serial MR Imaging Registry
The research study procedures include:
|
Imaging with MRI will be performed as per disease site standards.
|
Experimental: Vulvar Cancer Cohort
The research study procedures include:
|
Imaging with MRI will be performed as per disease site standards.
|
Experimental: Pediatric Glioma Cohort
The research study procedures include:
|
Imaging with MRI will be performed as per disease site standards.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of acquiring serial MRI scans on an MRI simulator during treatment with radiation therapy
Time Frame: 1 year
|
90% lower confidence limit (LCL) on the true feasibility rate.
Feasibility is defined as successfully enrolling patients, acquiring MRI data at all timepoints, identifying the target on MRI data obtained at all timepoints, and processing MRI data at all timepoints to yield pre-specified MRI-derived measurements.
|
1 year
|
Ability to measure disease control (for imaging registry expansion cohort)
Time Frame: 2 years
|
Validating a previously developed predictive model to identify the most likely area of recurrence using MRI-based features.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosimetric change
Time Frame: 1 year
|
For subprotocols studying the adaptive treatment, the secondary objective is dosimetric change in the in silico adaptive radiation therapy plans, without delivering adaptive plans in Phase I.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Leeman, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genital Neoplasms, Male
- Prostatic Diseases
- Head and Neck Neoplasms
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Esophageal Diseases
- Vulvar Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Genital Diseases, Female
- Prostatic Neoplasms
- Glioblastoma
- Vulvar Neoplasms
- Esophageal Neoplasms
Other Study ID Numbers
- 19-573
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRI
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
PfizerCompletedMRI SedationUnited States, Japan
-
University of UtahWithdrawnMRI ScansUnited States
-
Rennes University HospitalRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of LiegeUnknown
-
SpinTech, Inc.University of Iowa; University of Texas Southwestern Medical Center; Loma Linda... and other collaboratorsCompleted
Clinical Trials on MRI IMAGING
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); University of Iowa; Oregon Health and Science... and other collaboratorsRecruiting
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMetastatic Malignant Neoplasm in the Brain | Invasive Malignant NeoplasmUnited States
-
American College of RadiologyPennsylvania Department of HealthCompleted
-
Children's Hospital Los AngelesRecruitingTBI (Traumatic Brain Injury) | Hypoxic-Ischemic Encephalopathy | Hemodynamic Instability | TBI | HIEUnited States
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingShoulder InjuriesFrance
-
Heuron Inc.Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBrain NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterWithdrawn
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Recruiting